100
Participants
Start Date
July 31, 2010
Primary Completion Date
February 29, 2012
Study Completion Date
February 29, 2012
Whole peanut extract
Four different doses of whole peanut extract expressed as micrograms (mcg) of peanut proteins (20, 100, 250, 500 mcg) and two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested for determination of the maximum tolerated dose during a 2-week treatment period.
Placebo formulation
Matching placebo at two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested in parallel to the peanut proteins doses for determination of the maximum tolerated dose during a 2-week treatment period.
Duke University Medical Center, Durham
Arkansas Children's Hospital, Little Rock
National Jewish Health, Denver
Aspen Clinical Research, Orem
CRI Worldwide, Willingboro
Lead Sponsor
DBV Technologies
INDUSTRY